**Table 1. Demographics for patients that underwent reconsidered Surgical Aortic Valve Replacement (rSAVR)**

|  |  |
| --- | --- |
|  |  |
|  | **n (%)/ median [IQR]** |
| Mean age | 80 [73.5-85] |
| BMI | 27.1 [23.9-30.8] |
| Male gender | 47 (52.2) |
| CCS III-IV | 8 (8.9) |
| NYHA III-IV | 47 (52.2) |
| Prior MI | 7 (7.8) |
| Diabetes | 13 (14.4) |
| Hypertension | 58 (65.2) |
| Smoking history | 58 (65.2) |
| PVD | 7 (7.8) |
| Renal dysfunction | 3 (3.3) |
| LVEF <30% | 5 (5.6) |
| Mean logEuroSCORE | 8 (6-10) |
| Multiple procedures\* | 14 (15.7) |
| Neurological history | 9 (10) |
| Pulmonary disease | 35 (39.3) |
| *\*Any cardiac procedure in addition to rSAVR* | |

**Table 2 – Operative characteristics of reconsidered Surgical Aortic Valve Replacement (rSAVR) group**

|  |  |  |  |
| --- | --- | --- | --- |
|  |  | **n/median** | **% [IQR]** |
| CBT |  | 94 | [73.5-131] |
| CCT |  | 64 | [50.5-85] |
| Number of grafts | | 1 | [0-2] |
| Aortic valve size | | 23 | [21-23] |
| Other procedures | |  |  |
|  | CABG | 30 | 33.3 |
|  | AF ablation | 3 | 3.3 |
|  | Myomectomy | 1 | 1.1 |
|  | Peripheral vascular | 6 | 6.7 |
|  | Other | 3 | 3.3 |
| Number of valves replaced | |  |  |
|  | 1 | 84 | 93.3 |
|  | 2 | 3 | 3.3 |
|  | 3 | 2 | 2.2 |
| Aortic valve hemodynamics | |  |  |
|  | Stenosis | 63 | 70.0 |
|  | Regurgitation | 6 | 6.7 |
|  | Mixed | 21 | 23.3 |
|  |
| *IQR: interquartile range, CBT: cumulative bypass time, CCT: cumulative crossclamp time, CABG: coronary artery bypass grafting, AF: atrial fibrillation.* | | | | |

**Table 3. Reasons for denial of transcatheter aortic valve implantation (TAVI) after multidisciplinary team discussion**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **Conservative (n=405)** | | **rSAVR**  **(n=114)** | |  |
|  | **N** | **%** | **n** | **%** | **P value** |
| **Technical/procedural** |  |  |  |  |  |
| Vascular access | 35 | 8.6 | 6 | 5.3 | <0.001 |
| Coronary anatomy/concomitant disease | 29 | 7.2 | 23 | 20.2 |  |
| Mitral or complex valve disease | 23 | 5.7 | 5 | 4.4 |  |
| Root/AV difficulties | 25 | 6.2 | 15 | 13.2 |  |
| **Clinical/patient related** |  |  |  |  |  |
| Patient's wishes | 13 | 3.2 | 4 | 3.5 | <0.001 |
| High risk/multiple comorbidities | 195 | 48.1 | 23 | 20.2 |  |
| Minimal symptoms/asymptomatic | 52 | 12.8 | 17 | 14.9 |  |
| Other | 33 | 8.1 | 21 | 18.4 |  |

*rSAVR: reconsidered Surgical Aortic Valve Replacement*

**Table 4. Outcomes of reconsidered Surgical Aortic Valve Replacement (rSAVR)**

|  |  |  |  |
| --- | --- | --- | --- |
|  |  | **n/median** | **% [IQR]** |
| Length of stay | | 10.5 | [8-15.3] |
| New neurological events  TIA/RIND/stroke | | 7 | 7.8 |
| Stroke | | 4 | 4.4 |
| Postop dialysis | | 0 | 0.0 |
| Deep sternal wound infection | | 0 | 0.0 |
| Inhospital mortality | | 2 | 2.2 |
| Disposition | |  |  |
|  | Home | 54 | 60.0 |
|  | Convalescence | 28 | 31.1 |
|  | Acute hospital | 5 | 5.6 |
| Reoperation for bleeding | | 3 | 3.3 |

*TIA – transient ischemic attack*

*RIND – reversible ischemic neurological deficit*

**Table 5. Cox proportional hazards model for long term survival in reconsidered Surgical Aortic Valve Replacement (rSAVR) at the time of rSAVR vs at multidisciplinary evaluation**

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Risk factors at the time of rSAVR** | | | | | | | | |
|  | **Univariable** | | | | **Multivariable** | | | |
|  | **HR** | **95% CI** | | **P value** | **HR** | **95% CI** | | **P value** |
| Euroscore | 0.98 | 0.84 | 1.14 | 0.752 |  |  |  |  |
| Age | 1.04 | 0.99 | 1.10 | 0.121 | 1.04 | 0.99 | 1.09 | 0.113 |
| Male gender | 1.88 | 0.80 | 4.39 | 0.147 | 1.59 | 0.67 | 3.77 | 0.288 |
| CCS III-IV | 0.58 | 0.13 | 2.50 | 0.461 |  |  |  |  |
| NYHA III-IV | 0.58 | 0.26 | 1.30 | 0.187 | 0.60 | 0.26 | 1.39 | 0.235 |
| Prior MI | 2.08 | 0.62 | 7.00 | 0.236 |  |  |  |  |
| DM | 0.98 | 0.29 | 3.28 | 0.967 |  |  |  |  |
| Smoking history | 1.55 | 0.64 | 3.79 | 0.334 |  |  |  |  |
| PVD | 1.91 | 0.57 | 6.42 | 0.295 |  |  |  |  |
| Hypertension | 0.73 | 0.31 | 1.69 | 0.462 |  |  |  |  |
| LVEF <30% | 0.87 | 0.12 | 6.48 | 0.893 |  |  |  |  |
| Multiple procedures | 0.41 | 0.10 | 1.73 | 0.223 |  |  |  |  |
| Neurological history | 3.28 | 1.22 | 8.82 | 0.019 | 3.10 | 1.14 | 8.41 | 0.027 |
| **Risk factors at multidisciplinary evaluation** | | | | | | | | |
|  | **HR** | **95% CI** | | **P value** | **HR** | **95% CI** | | **P value** |
| rSAVR | 0.33 | 0.24 | 0.46 | <0.001 | 0.37 | 0.26 | 0.51 | <0.001 |
| Octogenarian | 1.04 | 0.82 | 1.32 | 0.716 | 0.99 | 0.78 | 1.26 | 0.96 |
| High comorbidities | 1.86 | 1.46 | 2.36 | <0.001 | 1.57 | 1.19 | 2.07 | 0.001 |
| Technical reason for denial | 0.7 | 0.53 | 0.93 | 0.013 | 1.00 | 0.72 | 1.39 | 0.998 |
| *HR: hazards ratio, CCS: Canadian Cardiovascular Society, NYHA: New York Heart Association, MI: myocardial infarction, PVD: peripheral vascular disease, LVEF: left ventricular ejection fraction* | | | | | | | | |